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Abstract  
This study aims to analyse an impact immunohystochemical (IHC) factors have on thermography findings 
depending on IHC phenotype of invasive breast tumor. Protein HER-2 status, as a prognostic and predictive factor, 
has so far not been a subject of thermographic tests. According to IHC profile of all parameters on temperature 
scale, going from the coldest to the warmest tumors group, an impact on measured temperatures was 
proportionate to an individual and common impact of the analysed IHC factors. According to the results of this 
study, the tumors that are thermographically warmer have poorer IHC parameters. Thermographically colder 
tumors could be represented by those with the best as well as by those with the worst prognostic IHC parameters.   
    
 Introduction 
Infrared thermography (IR) as a diagnostic method used for early detection, diagnostics and prognosis of breast 
tumors. Malignant tumor is the most important finding that can be detected in a thermogram. The practice had 
positively confirmed that thermal response is directly proportionate to biological activity of tumor. An intensified 
blood flow is indicated as hyperthermia and hipervascularity and directly related to the level of biological activity of 
tumor. Regardless whether this is an issue of metabolism or immunologic reaction, temperature is always 
increased. The tumor size is not directly related with degree of hyperthermia. Hyperthermia varies, and in extreme 
cases of inflammatory carcinoma a temperature increase was recorded in absolute value of 6ºC compared to a 
normal breast (2,3). Immunohystochemical (IHC) reaction of invasive breast tumors to ER, PR, HER-2 reflects 
tumor biological aggression, which directly affects the disease prognosis. Earlier thermographic studies have 
shown that some IHC factors could determine aggression of invasive breast tumor by thermobiological signs. This 
study intends to analyse an impact on thermography findings of HER-2 status as a prognostic and predictive 
factor, which has so far not been a subject of thermographic tests combined with other IHC factors, depending on 
IHC phenotype of an invasive breast tumors. 
Patients and methods 
The study was prepared at the Sister of Mercy Clinical Hospital, Oncologic Surgery Department and Pathology 
Department, in collaboration with licensed IC thermography experts from the University of Zagreb Faculty of 
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Mechanical Engineering and Naval Architecture Department of Thermodynamics, Thermal and Process 
Engineering. The study involved 130 female patients examined during a one-month period in 2011. The patients 
with indication for surgical treatment of suspected breast changes were pre-operatively examined using 
thermography. After surgical treatment and obtained patohistological diagnosis (PHD), 75 patients who were 
diagnosed with invasive breast tumor remained in the study. Thermography was carried out using thermographic 
system ThermaCAM 2000, under ambulatory conditions, in an air-conditioned 4x3 m room, and constant humidity 
and temperature of 22-23 ºC. The imaging was carried out with patients in sitting position, their arms on the back 
of the head, with maximum inspiration, from a distance of 80 cm. A front image was made of thorax with axilla, 
both in right and left oblique projections.     
The patohistological diagnosis contained parameters analysed in the study, which are also routinely determined 
immunohystochemically for breast carcinoma, i.e. hormone receptors (estrogen and progesterone) and protein 
HER-2. 
To determine expression of estrogen and progesterone receptors and HER-2 in tumor cells of the primary breast 
carcinoma, immunohystochemical staining was carried out in an automatic DakoAutostainer at room temperature. 
Prepared tissue slides were treated with primary mice monoclonal ERα antibodies (DAKO; M 7047; 1:50) and PR 
(DAKO; M 3569; 1:75), according to the manufacturer's protocol, by HRP/DAB method of secondary antibody 
conjugated with peroxidase and DAB chromogene (Dako Danmark). HER-2 expression determination (Kit HER-2, 
DAKO; K 5207; ready to use) is done routinely using Hercep Test® which is, according to the manufacturers 
protocol, a modification of the mentioned IHC method (Dako Denmark). According to the immunohystochemical 
reaction of breast tumor to estrogen and progesterone receptors, the result is considered negative if reactivity was 
indicated for less than 10% tumour cells, namely nucleus. As positive findings for HER-2 were considered those 
with 3+ or 2+, and clearly confirmed by a chromogenic in situ hybridisation (CISH) or, when the CISH finding is 
not clear, by fluorescence in situ hybridisation (FISH). 
IR image (thermogram), namely the measurement results were analysed using a computer program ThermaCAM-
Researcher. A “field” analysis tool was used to measure: maximum, minimum and average values and standard 
deviation of temperature of tumor, entire breast with tumor, on a healthy breast side opposite to that of the tumor, 
and the entire healthy breast.   
Thermographic findings were used for comparison with obtained parameters of IHC findings, showing their impact 
on temperature data, in line with the characteristics given to a particular group of patients with invasive breast 
tumor. 
  
A statistical analysis of data was carried out with SPSS program for Windows 17 (SPSS Inc., Chicago, Il). The 
distribution normality was tested with a one-way Kolmogorov-Smirnov test. The statistical analysis included 
descriptive statistics, Student t-test for dependent and independent samples, and a one-way variance analysis 
(one-way ANOVA). 
 
Results 
 The study included 75 patients with invasive breast tumor, aged 36 to 86 years. Mean age was 64 ±11.36 years.   
Of total, 30 patients (40%) had tumor in right breast and 45 (60%) in left breast. Most patients, 58, had ductal 
invasive tumor, 5 patients had lobular invasive tumor, and 12 patients had some other hystological type of tumour: 
papillar, mucinous, tubular, medullary, malignant filodes or neuroendocrine tumor. 
According to the histological grade,13 patients had grade I, 38 grade II, and 22 patients had grade III tumor. Of 
total number, 50 patients had no positive axillary metastases (68%), while 25 patients had positive axillary lymph 
nodes (32%). Distant metastases were found in 3 patients (4%) only. 
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Among all the patients with invasive breast tumor, 56 had estrogen positive receptors (77%), and 17 (23%) had 
estrogen negative receptors, 44 patients (60%) had positive progesterone receptors, and 29 had negative 
progesterone receptors (40%). Altogether 14 patients (19%) had positive HER-2, and 59 patients (81%) had 
negative HER-2. Table 1 shows arithmetic means (x), standard deviations (SD), and minimum and maximum 
temperatures in tumor site and entire breast with tumor, and  in healthy breast side opposite to that of the tumor 
and in entire healthy breast. 
Table  1. Arithmetic means (x), standard deviations (SD), and minimum and maximum temperatures in tumor site 
and entire breast with tumor, and  in healthy breast side opposite to that of the tumour and in entire healthy 
breast. 
Variable x SD 
Maximal temperature - tumor 35,75 1,05 
Maximal temperature opposite side tumor in health 
breast   
34,92 1,36 
Average temperature - tumor 34,96 1,16 
Average temperature opposite side tumor in health 
breast     
34,20 1,30 
Maximal temperature breast with tumor    36,09 0,94 
Maximal temperature health breast 35,85 1,08 
Average temperature breast with tumor    34,39 1,51 
Average temperature  health breast 33,94 1,37 
  
Table 2 shows testing of significance of differences between arithmetic means of temperatures for tumor and the 
opposite side, as well as for the entire breast with tumor and healthy breast, for maximum measured and average 
temperatures. A statistically significant difference was recorded in all cases, namely the tumor and the breast with 
tumor were statistically significantly warmer (p<0.001) than the opposite side.   
Table  2. Testing significance of differences between arithmetic means of temperatures measured in healthy and 
breast with tumor. 
 
Variable 
Average temperature - tumor - 
Average temperature opposite side 
tumor in health breast   
Average temperature breast with tumor 
-  Average temperature  health breast 
Maximal temperature tumor - Maximal 
temperature opposite side tumors in 
health breast    
Maximal temperature  breast with 
tumor    - Maximal temperature  health 
breast 
 
 
x 
 
SD 
 
t 
 
df 
 
p 
0,76 0,75 8,94 74 <0,001 
0,45 0,96 4,04 74 <0,001 
0,840 0,79 9,17 74 <0,001 
0,240 0,56 3,70 74 <0,001 
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Descriptive statistics and testing significance of differences between measured temperatures depending on tumor 
positive or negative estrogen receptors is shown in table 3.  Levene test indicated equality of variances between 
positive and negative group, and the degree of freedom was 71. There were no statistically significant differences 
(p>0.05) between the patients with positive (N=56) and negative (N=17) tumor receptors for estrogen, with 
possibility of error of 5% (i.e. probability of 95%). 
Table 3 shows that group with ER- has higher maximum and average tumor temperature as compared to the 
group with ER+. It is also indicated that the group with ER+ has higher maximum and average temperature of the 
entire breast with tumor as compared to the group with ER-. 
Table  3. Testing significance of difference between patients with tumors with positive and negative estrogen 
receptors (Student t-test for independent samples). 
   
 ER 
 
N 
 
x 
 
SD 
 
t 
 
p 
Maximal temperature - tumor  - 17 35,81 0,72 0,49 0,62 NS 
 + 56 35,67 1,09 
Average temperature - tumor   - 17 35,03 0,75 0,46 0,65 NS 
 + 56 34,88 1,24 
Maximal temperature  breast with tumor  - 17 36,02 0,67 -0,18 0,86 NS 
 + 56 36,06 0,97 
Average temperature breast with tumor   - 17 34,29 0,94 -0,21 0,83 NS 
 + 56 34,38 1,66 
Maximal temperature opposite side tumor 
in health breast   
 - 17 35,05 0,98 0,64 0,52 NS 
 + 56 34,81 1,44 
Average temperature opposite side tumor 
in health breast      
 - 17 34,11 1,12 -0,17 0,86 NS 
 + 56 34,17 1,34 
Maximal temperature health breast     - 17 35,69 0,69 -0,52 0,60 NS 
 + 56 35,85 1,15 
Average temperature health breast     - 17 33,78 1,13 -0,41 0,68 NS 
 + 56 33,94 1,44 
Difference  average temperature tumor and  
opposite side   - 17 
0,92 0,78 1,01 0,31 NS 
 + 56 0,71 0,73 
Difference  average temperature breast 
with tumor and health breast       - 17 
0,51 0,43 0,24 0,81 NS 
 + 56 0,44 1,09 
 
Descriptive statistics and testing significance of difference between measured temperatures depending on 
positive or negative progesterone receptors in tumor is shown in table 4. Levene test indicated equality of 
variances between positive and negative group, and the degree of freedom was 71. The Student t-test for 
independent samples generally indicated no statistically significant differences (p>0.05) (with possibility of error of 
5%) between the patients with progesterone positive receptor tumors (N=44) and those with progesterone 
negative tumor receptors (N=29). The only statistical significance (with possibility of error of more than 1%) 
(p>0.01) was noted for arithmetical means for maximum temperatures and average temperatures of tumors, 
which were considerably higher for progesterone negative than for progesterone positive tumors (p<0.05).  
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Table  4. Testing significance of difference between patients with tumors with positive and negative progesterone 
receptors (Student t-test for independent samples). 
   
PR 
 
N 
 
x 
 
SD 
 
t 
 
p 
Maximal temperature - tumor  
  
 - 29 36,01 0,77 2,14 0,036* S 
 + 44 35,51 1,11 
Average temperature - tumor  
 
 - 29 35,31 0,84 2,5 0,015* S 
 + 44 34,66 1,25 
Maximal temperature  breast with 
tumor  
 - 29 36,25 0,70 1,55 0,126 NS 
 + 44 35,92 1,00 
Average temperature breast with tumor   - 29 34,65 1,01 1,35 0,18 NS 
 + 44 34,16 1,75 
Maximal temperature opposite side 
tumor in health breast   
 - 29 35,24 1,00 1,96 0,054 NS 
 + 44 34,63 1,49 
Average temperature opposite side 
tumor in health breast       
 - 29 34,42 1,13 1,46 0,15 NS 
 + 44 33,98 1,35 
Maximal temperature health breast     - 29 35,98 0,72 1,07 0,29 NS 
 + 44 35,71 1,23 
Average temperature health breast   - 29 34,22 1,16 1,61 0,11 NS 
 + 44 33,70 1,47 
Difference  average temperature tumor 
and  opposite side   - 29 
0,89 0,68 1,22 0,23 NS 
 + 44 0,68 0,78 
Difference  average temperature breast 
with tumor and health breast       - 29 
0,43 0,42 -
0,14 
0,89 NS 
 + 44 0,47 1,22 
 
When significance of difference between arithmetic means of maximum or average temperatures was tested for 
patients with HER-2 positive and HER-2 negative tumors, the Student t-test for independent samples indicated 
statistically significant differences (p<0.05) (possibility of error of 5%, i.e. probability 95%) between the patients 
with HER-2 positive tumors (N=14) and the patients with HER-2 negative tumors (N=59) for the following 
variables: maximum tumor temperature, average tumor temperature, maximum temperature of the entire breast 
with tumor and difference between an average temperature of tumor and the side opposite to that of the tumor. 
The arithmetic means of maximum and average temperature of tumors, arithmetic means of maximum 
temperatures of breast with tumors, and the difference between the average temperature of tumor and the side 
opposite to that of the tumor were significantly higher for HER-2 positive than for HER-2 negative tumors 
(p<0.05). A variable “average temperature of entire breast with tumor” showed no statistically significant 
difference between HER-2 positive and negative tumors, but arithmetic means were higher for HER-2 positive 
tumors, and would be significantly higher with possibility of error of 11% (p =0.11). Descriptive statistics and 
testing of significance of difference between measured temperatures depending on positive or negative HER-2   
in tumor is shown in table 5. Levene test indicated equality of variances between HER-2 positive and negative 
group, therefore the degree of freedom was 71.  
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Table  5. Testing significance of difference between patients with tumors with positive and negative HER-2 
(Student t-test for independent samples). 
    
 HER-2 
 
N 
 
x 
 
SD 
 
t 
 
p 
Maximal temperature - tumor  - 59 35,60 0,97 -1,98 0,048 *S 
 + 14 36,17 1,10 
Average temperature - tumor  - 59 34,78 1,15 -2,15 0,035* S 
 + 14 35,49 0,97 
Maximal temperature  breast with 
tumor  
 - 59 35,92 0,91 -2,60 0,012* S 
 + 14 36,59 0,68 
Average temperature breast with 
tumor  
 - 59 34,22 1,60 -1,60 0,11 NS 
 + 14 34,94 0,89 
Maximal temperature opposite side 
tumor in health breast   
 - 59 34,80 1,36 -0,91 0,365 NS 
 + 14 35,16 1,28 
Average temperature opposite side 
tumor in health breast      
 - 59 34,08 1,31 -1,08 0,284 NS 
 + 14 34,49 1,15 
Maximal temperature health breast    - 59 35,68 1,09 -2,23 0,029 *S 
 + 14 36,36 0,74 
Average temperature health breast    - 59 33,76 1,42 -1,195 0,06 NS 
 + 14 34,52 0,92 
Difference  average temperature 
tumor and  opposite side  - 59 
0,71 0,79 -1,978 0,048 *S 
 + 14 1,01 0,44 
Difference  average temperature 
breast with tumor and health breast     - 59 
0,46 1,08 0,172 0,86 NS 
 + 14 0,41 0,22 
 
 
 According to a combination of analysed IHC factors of invasive tumors in all patients in this study, different 
groups of patients with the same IHC tumor phenotype were created. They formed temperature scales starting 
from a group of patients with the lowest recorded average temperature of the tumor itself and breast with tumor, 
going towards groups with higher average temperatures, and ultimately to a group with the highest recorded 
average temperature of the tumor and the breast with tumor. The lowest average temperature was recorded in 
the group of patients with positive hormone receptors and negative HER-2 . The highest average temperature of 
the tumor and the breast with tumor was recorded in the group of patients with  ER+, PR-, HER+ ( table 6). 
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 Table 6. Temperature scale of arithmetic means of temperatures measured in tumor and in breast with tumor 
depending on immunohystochemical phenotype of tumor (ER, PR and HER-2). 
 
n  ER  PR  HER-2  Average    
tumor 
temp 
Average 
temp 
 breast + tm    
Average  
size tm (mm3) 
 Average  
grade  
tumor  
41 + + - 34,58 34,09 16254,00 1,85 
11 - - - 34,95 34,15 5418,27 2,55 
6 - - + 35,18 34,53 18577,00 2,83 
7    + - - 35,70 35,11 3396,86 2,29 
5 + - + 35,74 35,24 8863,20 2,40 
 
 
Table 7 shows testing significance of difference between average tumor temperatures between (ER+, PR+, HER-
2-) tumors and (ER+, PR-, HER-2+) tumors. As shown, the average temperature of ER+, PR+, HER-2- tumors is 
statistically significantly lower (p<0.05) than for ER+ ,PR-, HER-2+ tumors. 
 
Table7. Testing significance of difference between average tumor temperatures for (ER+, PR+, HER-2-) tumors 
and (ER+, PR-, HER-2+) tumors. 
 
Phenotype of tumor        ER+,PR+,HER-2- ER+,PR-,HER-2+ 
Aritmetic mean 34,58 35,74 
Variance 1,46 0,988 
n 41 5 
df 44  
t  -2,06  
P(T<=t) ) one-way 0,02*S  
Critical t test for sigle 1,68  
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Discussion 
All previous thermographic studies have indicated that larger tumors with metastases in regional lymph nodes as 
compared to smaller tumors, fast proliferating as compared to slowly proliferating, and less differentiated as 
compared to well differentiated, all have evidently more pathological thermobiological indicators, which is a 
characteristic of more aggressive invasive tumors (4,5,6). It has also been observed that more aggressive 
invasive tumors belong among the so called “warmer tumors” according to their thermographic findings, and that 
they directly affect shorter disease-free period and total survival of patients as compared to the so called “colder 
tumors” (1,8,10). Clinical value of IR thermography as a prognostic factor in patients with invasive breast tumors 
has in all previous thermographic studies been evaluated based on individual impact of clinical, patohistological 
and some IHC tumor parameters, namely based on size and number of their thermobiological pathological signs. 
The fact that during their aggressive growth invasive breast tumors cause an increase in temperature which is 
reflected on the body surface (skin) and which can be measured by IR thermography was confirmed by the first 
thermography findings within this study. Maximum and average temperature of both tumor and the entire affected 
breast was statistically significantly higher than maximum and average temperature of the side opposite to that of 
the tumor on healthy breast and entire healthy breast in all patients participating in this study.  
An analysis of the hormone receptor status in obtained findings show that ER- tumors had higher maximum and 
average temperature compared to ER+ tumors. It was also observed that ER- tumors had lower impact on 
warming of the entire breast, and that maximum and average temperature of the affected breast was higher in 
ER+ tumors. No statistically significant difference was determined in hormone receptor status between patients 
with ER+ and ER- tumors as regards measured temperatures.  
The obtained results on ER impact on thermographic findings from this study are similar to the results of the 
majority of earlier published thermographic studies. Only Sterns’ thermographic study determined that ER- impact 
on thermographic findings is greater than ER+ impact (7,9,10 ).  
As regards impact of the PR receptor status on thermographic findings, it is obvious that PR- tumors, compared to 
PR+ tumors, had a statistically significant impact in two temperature findings: maximum and average tumor  
temperature. Other findings also suggest a trend of PR- tumors having higher impact than PR+ tumors to 
maximum and average temperature of the entire breast with tumor, but the difference is not statistically 
significant.  
Other significant thermographic research, the results of which are referred to in this study, found no difference 
between progesterone receptors on thermographic findings (7,9,10 ).  
So far, no thermographic research has published results on impact the HER-2 have on thermographic findings of 
patients with invasive tumors. Results of this study point to the statistically significant impact of HER-2+ as 
compared to HER-2–in several temperature findings: for maximum and average tumor temperature, maximum 
and average temperature of breast with tumor, difference between an average tumor temperature and the side on 
a healthy breast opposite to that of the tumor. The increased temperature trend in HER-2 + tumors is also 
indicated in all other temperature findings and in healthy breast. The findings clearly indicate that HER+ status 
has the highest impact on all temperature measurement findings. 
According to a combination of analysed IHC factors of invasive tumors in all patients in this study, different groups 
of patients with the same IHC tumor phenotype were created. They formed temperature scales starting from a 
group of patients with the lowest recorded average temperature of the tumor itself and breast with tumor, going 
towards groups with higher average temperatures, and ultimately to a group with the highest recorded average 
temperature of the tumor and the breast with tumor. The lowest average temperature was recorded in the group 
of patients with positive hormone receptors and negative HER-2. The highest average temperature of the tumor 
and the breast with tumor was recorded in the group of patients with  ER+, PR-, HER+. 
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The analysis of the group of patients with the so called “cold” tumors shows presence of all IHC parameters that 
in previous analyses had the least impact on the thermographic findings, namely on average temperature of the 
tumor and the breast with tumor.  
Unlike this group, the analysis of the group of patients with the so called “warmest” tumors shows presence of all 
IHC parameters that in previous analyses had the highest and/or statistically significant impact on the 
thermographic findings, namely on average temperature of the tumor and the breast with tumor. 
Testing significance of difference between an average temperature of the tumor and breast with tumor in patients 
with the coldest invasive tumors (ER+, PR+, HER2-) and the patients with the warmest invasive tumors (ER+, PR- 
HER2+) shows that the group with cold tumors has a statistically significantly lower average temperature of the 
tumor and the breast with tumor.  
  
 
Conclusion 
The results of the study lead to the following conclusions:  
It was shown that positive HER-2 in five temperature findings, and PR negative receptors in two temperature 
findings, had the largest individual impact of IHC factors on thermographic findings. 
According to the IHC profile of all parameters on the temperature scale, from the group with the coldest to the 
group with the warmest tumors, the impact on measured temperature was proportionate to an individual and 
combined impact of the analysed IHC factors.     
According to the thermographic findings, the colder tumors could represent a group with the best IHC prognostic 
parameters. They could also represent a group with the worst IHC prognostic parameters, which is contrary to the 
observations from the thermographic research conducted so far. 
According to the thermographic findings for other groups on the temperature scale, the tumor warmth scale or 
gradation corresponds with the IHC prognostic factors where “warmer” tumor means poorer prognostic parameters, 
which is in line with the observations from other thermographic research. 
According to the results of this study, prognostic value of thermography in clinical use would be that 
thermographically warmer tumors could be said to have poor prognosis. For thermographically colder tumors, the 
difference between the best and worst prognosis group will be determined by clinical, patohistological and IHC 
parameters. 
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